drugset
Drugs / JNJ-40411813
last change Feb 2024 re-read 2 minutes ago

JNJ-40411813

also known as ADX71149

Small molecule targets GRM2 via activation

Developed for
schizophrenia · focal epilepsy · major depressive disorder
Investigated by
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Janssen Research & Development, LLC · Janssen Pharmaceutical K.K.

Trials 10 · a red edge is where a trial was stopped

today NCT04836559 · Ph 2 NCT04677530 · Ph 1 NCT01582815 · Ph 2 NCT01323205 · Ph 2 NCT01359852 · Ph 1 NCT01358006 · Ph 1 NCT01932333 · Ph 1 NCT01101659 · Ph 1 NCT01932320 · Ph 1 NCT01951053 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT04677530 Jan → May 2021 — Janssen Pharmaceutical K.K. Completed No outcome recorded
Phase 1 NCT01359852 Dec 2010 → Jul 2011 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01358006 Nov 2010 → Mar 2011 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01932333 May → Aug 2010 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01101659 Feb → Jul 2010 perceptual disorders, schizophrenia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01932320 Feb → May 2010 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 1 NCT01951053 Jan → May 2010 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT04836559 May 2021 → Feb 2024 focal epilepsy Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT01582815 Sep 2012 → Nov 2013 major depressive disorder Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT01323205 May 2011 → Nov 2012 schizophrenia Janssen Research & Development, LLC Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as JNJ 40411813 “The purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.” NCT01323205 ↗
10

NCT01951053 ↗

NCT01582815 ↗

NCT04677530 ↗

NCT01101659 ↗

NCT01932320 ↗

NCT01932333 ↗

NCT01359852 ↗

NCT01358006 ↗

NCT04836559 ↗

NCT01323205 ↗
Known as ADX71149 “Metabotropic glutamate receptor-2 positive allosteric modulator, JNJ-40411813 (ADX71149), was characterised for clinical effects in healthy volunteers in two phase-1 studies.” PMID 25735992 ↗ Mar 2015
Action Activate “Metabotropic glutamate receptor 2 positive allosteric modulator” CHEMBL3337527 ↗
1

“positive allosteric modulator of mGluR2” PMID 25735992 ↗ Mar 2015
Modality Small molecule — CHEMBL3337527 ↗
Route Oral “Patients will take JNJ-40411813 and placebo capsules orally (by mouth) twice daily (bid) with a meal.” NCT01323205 ↗
Target GRM2 “Metabotropic glutamate receptor 2 positive allosteric modulator” CHEMBL3337527 ↗